Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage biopharmaceutical company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, with a lead focus on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). This news page aggregates company-issued updates, press releases, and other coverage related to Pyxis Oncology’s oncology pipeline and corporate activities.
Readers can find announcements on preliminary and updated clinical data for micvotabart pelidotin (MICVO), the company’s first-in-concept ADC targeting extradomain-B of fibronectin in the tumor extracellular matrix. News items include results from Phase 1 monotherapy and Phase 1/2 combination studies in R/M HNSCC and other advanced solid tumors, as well as translational findings on MICVO’s three-pronged mechanism of action involving direct tumor cell killing, bystander effects, and immunogenic cell death.
In addition to clinical trial readouts, this feed features business and financial updates such as quarterly results, cash runway commentary, milestone payments from collaboration and license agreements, and information on royalty-related transactions. Corporate developments, including inducement equity grants, governance matters, and participation in investor and industry conferences, are also reflected in Pyxis Oncology’s news flow.
For investors, analysts, and others following PYXS, the news stream offers a consolidated view of how the company is advancing MICVO in monotherapy and in combination with pembrolizumab under a Clinical Trial Collaboration Agreement with Merck, as well as how it positions itself within the broader field of ADC-based cancer therapeutics. Regularly reviewing this page can help users track key clinical milestones, scientific presentations, and corporate disclosures that shape the company’s oncology development story.
Pyxis Oncology (NASDAQ: PYXS) announced positive preliminary data from its Phase 1 clinical trial of PYX-201, a novel antibody-drug conjugate targeting Extradomain-B Fibronectin. The drug achieved a 50% objective response rate including one complete response in head and neck cancer patients, and 26% overall response rate across six solid tumor types. PYX-201 demonstrated a favorable safety profile and dose-dependent responses. The company also announced a new clinical trial collaboration with Merck to evaluate PYX-201 in combination with KEYTRUDA®, with dosing expected to begin in Q1 2025.
Pyxis Oncology (NASDAQ: PYXS) reported Q3 2024 financial results and provided updates on its clinical programs. The company ended Q3 with $146.3 million in cash and investments, expecting runway into 2H 2026. The company has enrolled 80 patients in the PYX-201 Phase 1 trial and 45 patients in the PYX-106 trial. Q3 net loss was $21.2 million ($0.35 per share), compared to $23.0 million ($0.56 per share) in Q3 2023. R&D expenses increased to $17.7 million from $14.7 million, while G&A expenses decreased to $6.0 million from $10.7 million year-over-year.
Pyxis Oncology (Nasdaq: PYXS) announced an upcoming investor event on November 20, 2024, to present preliminary data from their Phase 1 clinical trial of PYX-201. The event will be held both in-person in New York City and virtually. The presentation will cover data from approximately 80 patients, including safety, preliminary efficacy, and pharmacokinetics results for PYX-201, a first-in-concept antibody-drug conjugate targeting Extradomain-B Fibronectin in solid tumors. Executive management will be joined by physician thought leaders Dr. Anthony Tolcher and Dr. Glenn Hanna to discuss the findings and future development plans.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company developing next-generation cancer therapeutics, has announced its participation in two upcoming investor conferences. CEO Lara S. Sullivan will engage in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 at 12:20 PM ET and the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 2:00 PM ET, both in New York.
Management will also participate in one-on-one meetings during these events. Investors can access live webcasts and replays of the presentations through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.
Pyxis Oncology (PYXS) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Preliminary data from PYX-201 Phase 1 trial expected in fall 2024
- Preliminary data from PYX-106 Phase 1 trial expected by year-end 2024
- Cash runway extended into 2H 2026
- $157.2 million in cash and investments as of June 30, 2024
- 72 subjects dosed in PYX-201 trial, 33 in PYX-106 trial
- Q2 2024 R&D expenses: $13.9 million (up from $11.4 million in Q2 2023)
- Q2 2024 net loss: $17.3 million or ($0.29) per share
The company remains focused on developing next-generation therapeutics for difficult-to-treat cancers, with ongoing clinical trials for PYX-201 and PYX-106.
Pyxis Oncology, a clinical stage company developing next-gen cancer therapies, announced its participation in the BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Lara S. Sullivan, M.D., President and CEO of Pyxis, along with other management members, will engage in one-on-one meetings during the conference.
This participation highlights Pyxis Oncology's commitment to advancing its pipeline of therapeutics targeting difficult-to-treat cancers. The company's presence at this virtual event provides an opportunity for investors and industry professionals to gain insights into Pyxis's ongoing developments and strategic direction in the oncology field.
Pyxis Oncology, a clinical stage company, announced the grant of restricted stock units and stock options to five new employees under its 2022 Inducement Plan. The total grants include 89,530 shares of common stock and options to purchase 111,913 shares at an exercise price of $3.31 per share. These awards, aligned with Nasdaq Listing Rule 5635(c)(4), serve as an inducement for employment and will vest over four years. The initial 25% of the grants will vest on the first anniversary, with the remaining shares vesting monthly over the subsequent three years.
Pyxis Oncology (Nasdaq: PYXS) has appointed Michael A. Metzger to its Board of Directors, effective June 10, 2024. Metzger brings over 25 years of biopharmaceutical experience and is currently the CEO of Syndax Pharmaceuticals. Pyxis CEO Lara S. Sullivan emphasized Metzger's expertise and leadership in innovation as vital for the company's growth, particularly in advancing their antibody-drug conjugates (ADCs) aimed at treating challenging cancers. Metzger expressed enthusiasm for contributing to Pyxis's mission of improving cancer treatment outcomes.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on next-generation cancer therapeutics, announced that its President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 AM Eastern Time in New York City. The management team will also hold one-on-one meetings with investors. The event will be webcast live, with a replay available on the company's Investor Relations website.
Pyxis Oncology (Nasdaq: PYXS) announced its Q1 2024 financial results and corporate updates. PYX-201's Phase 1 trial has dosed 42 patients and aims to dose 16 more, with readout expected in fall 2024. PYX-106's Phase 1 trial, targeting NSCLC and other cancers, has dosed 24 patients, with data expected in 2H 2024. The company presented new preclinical data and expanded its leadership team with Stephen Worsley as Chief Business Officer. Q1 2024 financial highlights include revenues of $16.1M, R&D expenses of $13M, and a net loss of $3.3M. Cash runway is expected to last into 2H 2026.